TY  - GEN
AU  - Han,H S
AU  - Diéras,V
AU  - Robson,M
AU  - Palácová,M
AU  - Marcom,P K
AU  - Jager,A
AU  - Bondarenko,I
AU  - Citrin,D
AU  - Campone,M
AU  - Telli,M L
AU  - Domchek,S M
AU  - Friedlander,M
AU  - Kaufman,B
AU  - Garber,J E
AU  - Shparyk,Y
AU  - Chmielowska,E
AU  - Jakobsen,E H
AU  - Kaklamani,V
AU  - Gradishar,W
AU  - Ratajczak,C K
AU  - Nickner,C
AU  - Qin,Q
AU  - Qian,J
AU  - Shepherd,S P
AU  - Isakoff,S J
AU  - Puhalla,S
TI  - Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
SN  - 1569-8041
PY  - 2019///0403
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Benzimidazoles
KW  - administration & dosage
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Breast Neoplasms, Male
KW  - Carboplatin
KW  - Female
KW  - Genes, BRCA1
KW  - Genes, BRCA2
KW  - Germ-Line Mutation
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasm Recurrence, Local
KW  - Paclitaxel
KW  - Placebos
KW  - Single-Blind Method
KW  - Temozolomide
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdx505
ER  -